Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.
(2013) In Cardiovascular Pathology 22(6). p.438-443- Abstract
- OBJECTIVES: To determine whether a long-term treatment with beta-blockers influences the inflammatory activity in carotid artery disease by reducing the carotid plaque levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), its enzymatic products lysophosphatidylcholine (lysoPCs), and of soluble urokinase plasminogen activator receptor (suPAR). MATERIALS AND METHODS: One hundred and thirty-four patients with significant symptomatic or asymptomatic carotid stenosis undergoing surgery were prospectively included and divided into two groups (Group A or B) based on the absence or presence of an on-going long-term oral treatment with beta-blockers. The harvested carotid plaques were analyzed for the levels of lysoPCs using mass... (More)
- OBJECTIVES: To determine whether a long-term treatment with beta-blockers influences the inflammatory activity in carotid artery disease by reducing the carotid plaque levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), its enzymatic products lysophosphatidylcholine (lysoPCs), and of soluble urokinase plasminogen activator receptor (suPAR). MATERIALS AND METHODS: One hundred and thirty-four patients with significant symptomatic or asymptomatic carotid stenosis undergoing surgery were prospectively included and divided into two groups (Group A or B) based on the absence or presence of an on-going long-term oral treatment with beta-blockers. The harvested carotid plaques were analyzed for the levels of lysoPCs using mass spectrometry and Lp-PLA2 and suPAR by Enzyme-linked immunosorbent assay (ELISA). RESULTS: Plaques of patients on long-term treatment with beta-blockers revealed lower levels of Lp-PLA2 (Group A 0.752±0.393 ug/g vs. Group B 0.644±0.445 ug/g, P=.049) as well as suPAR (Group A 0.044±0.024 μg/g vs. Group B 0.036±0.025 μg/g, P=.028). Levels of Lp-PLA2 and suPAR were positively correlated (r=.637, P<.0001). Lp-PLA2 and suPAR levels were also correlated (P<.0001) with the three lysoPC species tested (lysoPC 16:0, lysoPC 18:0. lysoPC 18:1). All the above-mentioned findings were confirmed after correction for age, gender, hypertension, coronary artery disease, and statin usage. CONCLUSIONS: The reduced levels of Lp-PLA2 and suPAR in human carotid plaques of subjects on long-term treatment with beta-blockers suggest their possible protective role in plaque inflammation. Our findings support an even more selective Lp-PLA2 and suPAR inhibition as a possible strategy for the prevention of cardiovascular disease. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3913610
- author
- Asciutto, Giuseppe LU ; Edsfeldt, Andreas LU ; Dias, Nuno LU ; Nilsson, Jan LU ; Prehn, Cornelia ; Adamski, Jerzy and Goncalves, Isabel LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cardiovascular Pathology
- volume
- 22
- issue
- 6
- pages
- 438 - 443
- publisher
- Elsevier
- external identifiers
-
- wos:000327153100004
- pmid:23747086
- scopus:84893660845
- ISSN
- 1879-1336
- DOI
- 10.1016/j.carpath.2013.04.005
- language
- English
- LU publication?
- yes
- id
- 542b62e8-b36d-452b-8299-828626691b89 (old id 3913610)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23747086?dopt=Abstract
- date added to LUP
- 2016-04-01 11:06:02
- date last changed
- 2022-04-28 07:09:53
@article{542b62e8-b36d-452b-8299-828626691b89, abstract = {{OBJECTIVES: To determine whether a long-term treatment with beta-blockers influences the inflammatory activity in carotid artery disease by reducing the carotid plaque levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), its enzymatic products lysophosphatidylcholine (lysoPCs), and of soluble urokinase plasminogen activator receptor (suPAR). MATERIALS AND METHODS: One hundred and thirty-four patients with significant symptomatic or asymptomatic carotid stenosis undergoing surgery were prospectively included and divided into two groups (Group A or B) based on the absence or presence of an on-going long-term oral treatment with beta-blockers. The harvested carotid plaques were analyzed for the levels of lysoPCs using mass spectrometry and Lp-PLA2 and suPAR by Enzyme-linked immunosorbent assay (ELISA). RESULTS: Plaques of patients on long-term treatment with beta-blockers revealed lower levels of Lp-PLA2 (Group A 0.752±0.393 ug/g vs. Group B 0.644±0.445 ug/g, P=.049) as well as suPAR (Group A 0.044±0.024 μg/g vs. Group B 0.036±0.025 μg/g, P=.028). Levels of Lp-PLA2 and suPAR were positively correlated (r=.637, P<.0001). Lp-PLA2 and suPAR levels were also correlated (P<.0001) with the three lysoPC species tested (lysoPC 16:0, lysoPC 18:0. lysoPC 18:1). All the above-mentioned findings were confirmed after correction for age, gender, hypertension, coronary artery disease, and statin usage. CONCLUSIONS: The reduced levels of Lp-PLA2 and suPAR in human carotid plaques of subjects on long-term treatment with beta-blockers suggest their possible protective role in plaque inflammation. Our findings support an even more selective Lp-PLA2 and suPAR inhibition as a possible strategy for the prevention of cardiovascular disease.}}, author = {{Asciutto, Giuseppe and Edsfeldt, Andreas and Dias, Nuno and Nilsson, Jan and Prehn, Cornelia and Adamski, Jerzy and Goncalves, Isabel}}, issn = {{1879-1336}}, language = {{eng}}, number = {{6}}, pages = {{438--443}}, publisher = {{Elsevier}}, series = {{Cardiovascular Pathology}}, title = {{Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.}}, url = {{https://lup.lub.lu.se/search/files/2379401/4144980.pdf}}, doi = {{10.1016/j.carpath.2013.04.005}}, volume = {{22}}, year = {{2013}}, }